Catalyst Wire Dossier Catalyst Wire Dossier

DI-Leu16-IL2

DI-Leu16-IL2 · Alopexx Oncology, LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for DI-Leu16-IL2, covering 2020-11-24 to 2020-11-27. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL [Phase 1, Phase 2]

See pricing